Drug Profile


Alternative Names: Forvade®; GS 504; HPMPC; Vistide

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague); Pfizer; Rega Institute for Medical Research; University of Texas M. D. Anderson Cancer Center
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cytomegalovirus retinitis
  • Phase I Cystitis
  • Discontinued Cancer; Herpes simplex virus infections; Human papillomavirus infections; Kaposi's sarcoma; Molluscum contagiosum; Polyomavirus infections; Rheumatic disorders; Viral infections

Most Recent Events

  • 01 Dec 2016 Gilead Sciences completes a phase I trial in Cystitis (in patients who have undergone haematopoietic stem cell transplant) in USA (Intravesicular) (NCT01816646)
  • 06 Sep 2013 Phase-I clinical trials in Cystitis (in patients who have undergone haematopoietic stem cell transplant) in USA (Intravesicular) (NCT01816646)
  • 03 Sep 2003 No development reported - Clinical-Phase-Unknown for Human papillomavirus infections in Belgium (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top